İnflamatuvar Barsak Hastalıklarında Laboratuvar Sonuçları ile Endoskopik Bulgular Arasındaki İlişki

Yıl 2024, Cilt: 6 Sayı: 2, 153 - 160, 30.06.2024

Mehtap Şahin , Nihat Okçu

https://doi.org/10.52827/hititmedj.1415074

Öz

Amaç: Bu çalışmanın amacı, inflamatuvar barsak hastalığı (İBH) olan olgularda rutin laboratuvar bulguları (hemoglobin, beyaz küre, trombosit, eritrosit sedimentasyon hızı (ESH), C-reaktif protein (CRP)) ile endoskopik tutulum alanları arasındaki ilişkiyi belirlemektir.
Gereç ve Yöntem: 2009-2015 yılları arasında Ülseratif Kolit (ÜK) ve Crohn Hastalığı (CH) tanısı alan hastaların tıbbi kayıtları geriye dönük olarak incelendi. Endoskopik bulgular ile kolonoskopi sırasındaki hemoglobin, beyaz kan hücresi, trombosit, ESR ve CRP değerleri kaydedildi. Laboratuvar parametreleri ile endoskopik tutulum lokalizasyonu arasındaki ilişkiyi incelemek için multinominal lojistik regresyon modeli oluşturuldu.
Bulgular: ÜK’te; ekstensif kolit/pankolit tutulumunda distal tip kolite göre hemoglobin değerinde anlamlı derecede düşüş saptanmışken (p=0.02), sol taraf kolitiyle distal tip kolit arasında anlamlı fark saptanmamıştır. Sol taraf koliti (p=0,007) ve ekstensif kolit/pankolit (p=0.043) tutulumunda distal tip kolite göre ESH değerleri belirgin yüksek bulunmuştur. CRP değeri sadece ekstensif kolit/pankolit tutulumunda anlamlı yüksek çıkmıştır (p=0.015). CH için laboratuvar parametreleri ile tutulum yerleri arasında herhangi bir ilişki bulunamamıştır.
Sonuç: ÜK'te hemoglobin değeri, ESR ve CRP düzeyleri tutulumun yerini belirlemede yardımcı olsa da CH’de etkileri görülmemiştir. Hastaların değerlendirilmesinde bu temel laboratuvar değerlerinin yanı sıra diğer parametrelerin de dikkate alınması gerekir.

Anahtar Kelimeler

C-reaktif protein, Crohn Hastalığı, eritrosit sedimentasyon hızı, Ülseratif kolit

The Relationship Between Endoscopic Findings and Laboratory Results in Inflammatory Bowel Diseases

Öz

Objective: The aim of this study was to determine the relationship between routine laboratory indicators [Including hemoglobin, white blood cells, platelets, erythrocyte sedimentation rate (ESR), and C-reactive protein (CRP)] and the extent of endoscopic involvement in individuals with inflammatory bowel disease (IBD).
Material and Method: The medical records of patients who were diagnosed with Ulcerative Colitis (UC) and Crohn’s Disease (CD) between 2009 and 2015 were retrospectively examined. Endoscopic findings and hemoglobin, white blood cell, platelet, ESR, and CRP values at the time of colonoscopy were analyzed. An exploratory multinomial regression model was created to examine the association of laboratory parameters and endoscopic involvement localization.
Results: In UC, a significant decrease in hemoglobin levels was present in cases with extensive colitis/pancolitis compared to distal type colitis (p=0.02), while no significant difference was found between left-sided colitis and distal type colitis. Elevated ESR values were notably found in left-sided colitis (p=0.007) and extensive colitis/ pancolitis (p=0.043) compared to distal type colitis. CRP levels were significantly higher in cases with extensive colitis/pancolitis (p=0.015). No relationship was identified between laboratory parameters and the endoscopic location of involvement in CD.
Conclusion: Although hemoglobin value, ESR and CRP levels are helpful in determining the location of involvement in UC, their effects have not been observed in CD. In addition to these basic laboratory values, other parameters should also be taken into consideration in the evaluation of patients.

Anahtar Kelimeler

C-reactive protein, Crohn, Erythrocyte Sedimentation Rate, Ulcerative Colitis

Kaynakça

• Guan Q. A Comprehensive Review and Update on the Pathogenesis of Inflammatory Bowel Disease. J Immunol Res 2019;7247238.
• Girardin M, Manz M, Manser C, et al. First-Line Therapies in Inflammatory Bowel Disease. Digestion 2012;86:6–10.
• Watermeyer G, Epstein D, Adegoke O, Kassianides C, Ojo O, Setshedi M. Epidemiology of inflammatory bowel disease in sub-Saharan Africa: A review of the current status. S Afr Med J 2020;110:1006-1009.
• Sobrado Junior CW, Villela Junior HM, Facanali CBG, Sobrado LF, de Camargo MGM, Nahas SC. Gastric and Duodenal Fistulas in Crohn’s Disease, a Surgical Challenge: Report of 5 Cases and a Review of the Literature. Am J Case Rep 2023;24:e940644.
• Emory TS, Sobin LH. Idiopatic Inflammatory Bowel Disease. In: Iacobuzio-Danahue CA. Montgomery EA, Goldblum JR, editors. Gastrointestinal and Liver Pathology, 1st ed. Philadelphia: Elsevier Churchill Livingstone: 2005;313-326.
• Awadhi SA, Alboraie M, Albaba EA, et al. Treatment of Patients with Mild to Moderate Ulcerative Colitis: A Middle East Expert Consensus. J Clin Med 2023;12:6929.
• Gros B, Kaplan GG. Ulcerative Colitis in Adults: A Review. JAMA 2023;330:951-965.
• Kohn A, Camastra CM, Monterubbianesi R, Rizzi M. Clinical Presentation. In Roberto Tersigni, Cosimo Prantera, editors. Crohn’s Disease Verlag,Italia: Springer: 2010;43-45.
• Baumgart DC, Sandborn WJ. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet 2007;369:1641-1657.
• Dulai PS, Jairath V. How Do We Treat Inflammatory Bowel Diseases to Aim for Endoscopic Remission? Clin Gastroenterol Hepatol 2020;18:1300-1308.
• Vermeire S, Van Assche G, Rutgeerts P. Laboratory markers in IBD: useful, magic, or unnecessary toys? Gut 2006;55:426-431.
• Walsh A, Mabee J, Trivedi K. Inflammatory bowel disease. Prim Care Clin 2011; 38:415-432.
• Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999;340:448-454.
• Kaiser T, Langhorst J, Wittkowski H. Faecal S100A12 as a non-invasive marker distinguishing inflammatory bowel disease from irritable bowel syndrome. Gut 2007;56:1706-1713.
• Kane SV, Sandborn WJ, Rufo PA. Fecal lactoferrin is a sensitive and specific marker in identifying intestinal inflammation. Am J Gastroenterology 2003;98:1309-1314.
• D’Haens G, Ferrante M, Vermeire S, et al. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease. Inflamm Bowel Dis 2012;18:2218-2224.
• Peyrin-Biroulet L, Standaert-Vitse A, Branche J. IBD serological panels: facts and perspectives. Inflamm Bowel Dis 2007;13:1561-1566.
• Reumaux D, Sendid B, Poulain D. Serological markers in inflammatory bowel diseases. Best Pract Res Clin Gastroenterol 2003;17:19-35.
• Koçhan K, Erdem E, Babacan G, et al. Correlation between clinical and endoscopic activity indices and laboratory parameters in determining the activity of inflammatory bowel disease. Akademik Gastroenteroloji Derg 2014;13:101-106.
• Önal İ, Beyazıt Y, Şener B, et al. The value of fecal calprotectin as a marker of intestinal inflammation in patients with ulcerative colitis. Türk J Gastroenterol 2012;509-514.
• Yeşil A, Şenateş E, Bayoğlu İ, et al. Red Cell Distribution Width: A Novel Marker Of Activity İn Infl Ammatory Bowel Disease. Gut and Liver 2011;460-467.
• Gasche C, Lomer MCE, Cavill I, Weiss G. Iron, anemia, and inflammatory bowel diseases. Gut 2004;1190–1197.
• Cronin CC, Shanahan F. Anemia in patients with chronic inflammatory bowel disease. Am J Gastroenterol 2001;2296-2298
• Kalaycı S, Kılıç Z, Özin Y, et al. Anemia and Serum Erythropoietin Levels in Patients with İnflammatory Bowel Disease. Akademik Gastroenteroloji Derg 2008;7:77-82.
• Iskandar HN, Ciorba MA. Biomarkers in inflammatory bowel disease: current practices and recent advances. Transl Res 2012;159:313-325.
• Alper A, Zhang L, Pashankar DS. Correlation of Erythrocyte Sedimentation Rate and C-Reactive Protein With Pediatric Inflammatory Bowel Disease Activity. J Pediatr Gastroenterol Nutr 2017;65:25-27.
• F Costa, M G Mumolo, L Ceccarelli, et al. Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn’s disease. Gut 2005;54:364-368.
• Lok KH, Ng CH, Hung HG, Li KF, Li KK, Szeto ML. Correlation of serum biomarkers with clinical severity and mucosal inflammation in Chinese ulcerative colitis patients. J Dig Dis 2008;9:219-224.
• Solem CA, Loftus EV Jr, Tremaine WJ, Harmsen WS, Zinsmeister AR, Sandborn WJ. Correlation of C-reactive protein with clinical, endoscopic, histologic, and radiographic activity in inflammatory bowel disease. Inflamm Bowel Dis 2005;11:707-712.
• Chouhan S, Gahlot S, Pokharna RK, Mathur KC, Saini K, Pal M. Severity and extent of ulcerative colitis: role of C-reactive protein. Indian J Gastroenterol 2006;25:46-47.
• Sarıtaş Yüksel E, İpek S, Topal F, et al. Assessment of presence and grade of activity in ileal Crohn’s disease. Türk J Gastroenterol 2014;25:264-270.
• Nogueıra I, Mıszputen S, Ambrogını Jr. O, et al. Assessment of The Response of Patients wıth Crohn’s Disease to Biologıcal Therapy Using New Non-Invasıve Markers: Lactoferrin and Calprotectin. Arq Gastroenterol 2013;50:130-137.
• Denis MA, Reenaers C, Fontaine F, et al. Assessment Of Endoscopic Activity Index And Biological Inflammatory Markers in Clinically Active Crohn’s Disease With Normal C-Reactive Protein Serum Level. Inflamm Bowel Dis 2007;13:1100-1105.
• Willot S, Vermeire S, Ohresser M, et al. C-reactive protein gene polymorphisms are not associated with biological or clinical response to infliximab in Crohn’s disease. Pharmacogenet Genomics 2006;16:37–42.